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Abstract. Background/Aim: The aim of this study was to
analyze the prognostic impact of serum lactate
dehydrogenase (LDH) in patients with oligometastatic brain
metastases, arbitrarily defined as max. Four brain lesions
and 5 metastatic lesions overall. Patients and Methods: This
was a retrospective single institution analysis. Overall, 42
patients were identified from a prospectively maintained
database. Results: Seventeen patients (40%) had
extracranial metastases. Twelve patients (29%) had elevated
LDH (≥255 U/l). Their median survival was significantly
shorter than that of patients with normal LDH. Due to an
interaction with performance status, this result was
separately confirmed in patients with performance status
≥70. Conclusion: Oligometastatic disease is not always
correctly diagnosed, because all radiological modalities are
limited by certain thresholds for detection of small
metastases. We hypothesize that LDH is associated with
survival, because this biomarker may reflect the total burden
of malignant disease. Future studies should examine whether
or not ablative local treatment of oligometastases is
warranted in patients with elevated LDH.  
Increasing attention has recently been paid to cancer patients
with oligometastatic disease, i.e. a state between curable
locoregional disease extension and incurable dissemination
throughout large parts of the body (1-4). If only few distant
metastases are present, ablative local treatment and/or
resection of all these lesions might result in longer survival
than historically observed (5-8). However, not all patients
become long-term survivors, a finding that emphasizes the
challenges associated with detecting true oligometastatic
disease. If additional micrometastases go undetected, rapid
disease progression might be encountered. It would, therefore,
be prudent to include staging examinations that are not
limited by the detection thresholds of radiological methods
(9, 10). For example, the number of circulating tumor cells
or other emerging biomarkers may aid in the detection of true
and pseudo-oligometastatic disease (11, 12). Given that many
patients, especially in low- and middle-income countries, lack
access to advanced imaging and biomarker evaluations,
widely available and inexpensive biomarkers may also
contribute to improved prognostic assessment and decision-
making. Based on our previous work on the prognostic
impact of serum lactate dehydrogenase (LDH) in patients
with brain metastases (13), we hypothesized that LDH might
reflect overall disease burden also in patients presumed to
harbor oligometastases. If true, patients with elevated LDH
due to otherwise undetectable additional metastases are
expected to have poorer survival and may spared the burden
of aggressive local treatment. This hypothesis was tested in a
previously utilized, continuously updated database (13, 14).   
Materials and Methods
Patients and treatment. A retrospective study of all patients with
maximum 4 parenchymal brain metastases from histologically
verified extracranial primary tumors treated with whole-brain
radiotherapy (WBRT) at our hospital was performed. Further
treatment was individualized and consisted of salvage radiosurgery
(SRS), systemic therapy or best supportive care (BSC). Systemic
treatment was usually prescribed as judged appropriate by the
patients’ medical oncologists. The patients were treated between
January 01, 2007 and December 31, 2017. Brain magnetic
resonance imaging (MRI) was performed to assess the number of
intracranial metastases and to exclude leptomeningeal disease.
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Extracranial staging consisted of computed tomography (CT).
Patients with extracranial metastases to one organ system, e.g.,
adrenal glands or distant lymph nodes (beyond regional drainage),
were included as long as the total number of metastases extra- and
intracranially was limited to five or fewer. LDH was assessed at the
start of WBRT or within the preceding week (the normal value was
defined as <255 U/l).  
Statistical methods. Overall survival (time to death) from the first
day of radiotherapy was calculated employing the Kaplan–Meier
method, and different groups were compared using the log-rank test
(SPSS 25, IBM Corp., Armonk, NY, USA). Only one patient was
censored after 49 months of follow-up. Date of death was known in
all other patients. A Cox forward conditional regression model was
employed for multivariate analysis. Statistical significance was
defined as p<0.05 throughout this study. 
Results
Patient characteristics. We identified 42 patients from the
database. Twenty-four (57%) had non-small cell lung cancer
(NSCLC). Seventeen patients (40%) had extracranial
metastases and the others brain-only dissemination. The
median age was 68 years (range=28-90 years). Further
patient characteristics are shown in Table I. 
Treatment. Eighteen patients (43%) received systemic
treatment. The typical WBRT regimen was 10 fractions of 3
Gy. Extracranial metastases were not treated with local
measures such as surgery or ablative radiotherapy. 
Survival. The median overall survival of all patients was 5.4
months (21% 1-year survival). As shown in Figure 1, LDH
was significantly associated with survival. Survival beyond
one year was observed in patients with normal LDH only.
Age, number of brain metastases, and presence of
extracranial metastases were not significantly associated with
elevated LDH. However, patients with elevated LDH were
more likely to have reduced performance status and higher
recursive partitioning analysis class (p=0.09, Chi-square
test). Performance status was more important in the
multivariate analysis than LDH, number of brain metastases
and presence of extracranial metastases (p=0.03 compared
to >0.4 for the three other variables). When excluding
patients with performance status <70 both log-rank test and
Cox regression analysis showed that LDH was the only
significant predictor of survival (p=0.03 in the multivariate
model with all four variables).  
Discussion
We performed a retrospective study of patients with a limited
number of brain metastases (between 1 and 4) and a
maximum number of five metastases in total, which involved
only one extracranial organ system, e.g., bilateral adrenal
gland metastases. Sixty percent had brain-only metastases.
We found that elevated LDH was associated with
significantly shorter survival, in line with our previous
results in a larger study of patients who mainly had non-
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Figure 1. Actuarial overall survival stratified by serum lactate
dehydrogenase (normal LDH: median 5.4 months, elevated LDH: median
3.3 months, p=0.03). 
Table I. Patient characteristics. 
Baseline parameter                                      Number                 Percent
Non-small cell lung cancer                              24                         57
Small cell lung cancer                                        9                         21
Breast cancer                                                       6                         14
Melanoma                                                            3                           7
Extracranial metastases                                    17                         40
Female gender                                                   18                         43
Male gender                                                      24                         57
One brain metastasis                                         16                         38
Two or three brain metastases                          21                         50
Four brain metastases                                         5                         12
Elevated lactate dehydrogenase                       12                         29
KPS 90-100                                                         2                           5
KPS 80                                                              10                         24
KPS 70                                                              15                         36
KPS <70                                                            15                         36
RPA class 1                                                         4                         10
RPA class 2                                                       23                         55
RPA class 3                                                       15                         36
KPS: Karnofsky performance status; RPA: recursive partitioning analysis.
oligometastatic brain metastases (13) and with other studies
in different settings (15-17). 
Limitations of the present study include the limited number
of patients, statistical power of subgroup analyses, and
retrospective design. The presence of oligometastatic disease
was not confirmed by positron emission tomography (PET)
staging. However, PET staging is also associated with false-
negative and otherwise inaccurate findings (10). Moreover,
PET capacity is limited or in some low- and middle-income
countries non-existent. Under these circumstances, readily-
available biomarkers might complement CT-based staging
with the ultimate goal of avoiding overtreatment in patients
with pseudo-oligometastatic disease. Emerging biomarkers
such as circulating tumor cells are not yet widely available, in
contrast to LDH measurement. 
We limited this analysis to patients treated with primary
WBRT in order to eliminate bias from differences in local
treatment. If some patients receive SRS, which results in
superior local control (18, 19), survival is no longer a
function of baseline prognostic parameters alone. As recently
shown, aggressive local treatment of oligometastatic cancer
appears to improve survival (5, 20). Compared to published
survival outcomes from studies employing more effective
local treatment our results are relatively disappointing (21%
1-year survival). In part, this can also be explained by the
selection of patients who were treated with primary WBRT
and the fact that patients with reduced performance status
were included. Notably, we found long-term survivors in the
group with normal LDH despite the absence of ablative local
treatment. Our results suggest that assessment of LDH may
add value when designing further clinical trials and also in
resource-limited settings. 
Conclusion
Oligometastatic disease is not always correctly diagnosed,
because all radiological modalities are limited by certain
thresholds for detection of small metastases. We hypothesize
that LDH is associated with survival, because this biomarker
may reflect the total burden of malignant disease. Future
studies should examine whether or not ablative local treatment
of oligometastases is warranted in patients with elevated LDH.  
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